Editors: Claude C. Schulman, Gary J. Kelloff

Strategies for the Chemoprevention of Prostate Cancer

Prostate cancer is a prime target for chemoprevention studies because of its long latency, high incidence and known risk factors; furthermore, hormonal dependency and precursor lesions are well documented.

To identify suitable populations for evaluation of potential chemopreventive agents and for future chemopreventive intervention, risk factors (such as the presence of early pre-malignant lesions and genetic predisposition) should be well characterized. Therefore, identification and characterization of intermediate biomarkers and their validation as surrogate endpoints for cancer incidence in clinical chemoprevention trials are significant components in the development of chemopreventive agents. Promising chemopreventive drugs of the prostate include retinoids, anti-androgens, antioestrogens, steroid aromatase inhibitors, 5 α -reductase inhibitors, vitamins D and E, selenium, lycopene and 2-difluoromethylomithine.

As a new concept in prostate cancer, chemoprevention should have a significant impact in the future on the incidence and mortality of this leading cancer threat in men.

Sections

Genetic and Environmental Factors in Prostate Cancer Genesis

Molecular Targets for Chemoprevention of Prostate Cancer

Preclinical Models for Drug Discovery

Surrogate Endpoint Biomarkers for Clinical Trials of Prostate Cancer Chemoprevention

Clinical Trial Designs for Chemoprevention of Prostate Cancer

Strategies for the Chemoprevention of Prostate Cancer

Symposium, Brussels, October 1998

Editors: Schulman C.C. (Brussels);

Kelloff G.J. (Bethesda, Md.)

IV + 210 p., 61 fig., 21 in color, 61 tab., hard cover, 1999

CHF 89.- / DEM 107.- / USD 77.50

European Urology

Editor: Schulman C.C. (Brussels)

ISSN 0302-2838

Hard-cover reprint:

Vol. 35, No. 5-6 (1999)

Prices subject to change

DEM price for Germany,

USD price for USA only

ISBN 3-8055-6866-5

Fields of Interest:

Urology; Chemotherapy; Oncology

KARGER

Contents

Kelloff, G.J. et al.: Chemoprevention of Prostate Cancer: Concepts and Strategies

Genetic and Environmental Factors in Prostate Cancer Genesis

Nupponen, N.; Visakorpi, T.: Molecular Biology of Progression of Prostate Cancer

Ross, R.K. et al.: Androgen Metabolism and Prostate Cancer: Establishing a Model of Genetic Susceptibility

Ekman, P.: Genetic and Environmental Factors in Prostate Cancer Genesis: Identifying High-Risk Cohorts

Boyle, P.; Severi, G.: Epidemiology of Prostate Cancer Chemoprevention

Denis, L.; Morton, M.S.; Griffiths, K.: Diet and Its Preventive Role in Prostatic Disease

Fradet, Y.; Meyer, F.; Bairati, I.; Shadmani, R.; Moore, L.: Dietary Fat and Prostate Cancer Progression and Survival

Molecular Targets for Chemoprevention of Prostate Cancer

Peehl, D.M.: Vitamin D and Prostate Cancer Risk

Myers, C.E.; Ghosh, J.: Lipoyxygenase Inhibition in Prostate Cancer

Moul, J.W.: Angiogenesis, p53, bcl-2 and Ki-67 in the Progression of Prostate Cancer after Radical Prostatectomy

Bussemakers, M.J.G.: Changes in Gene Expression and Targets for Therapy

Klocker, H. et al.: Mechanism of Androgen Receptor Activation and Possible Implications for Chemoprevention Trials

Sporn, M.B.: New Agents for Chemoprevention of Prostate Cancer

Whelan, P.: Retinoids in Chemoprevention

Urban, D. et al.: Evaluation of Biomarker Modulation by Fenretinide in Prostate Cancer Patients

Habib, F.K.; Ross, M.; Bayne, C.W.: Factors Controlling the Expression of 5 α -Reductase in Human Prostate: A Possible New Approach for the Treatment of Prostate Cancer

Griffiths, K.; Morton, M.S.; Denis, L.: Certain Aspects of Molecular Endocrinology That Relate to the Influence of Dietary Factors on the Pathogenesis of Prostate Cancer

Preclinical Models for Drug Discovery

Waters, D.J.: High-Grade Prostatic Intraepithelial Neoplasia in Dogs

Bosland, M.C.: Use of Animal Models in Defining Efficacy of Chemoprevention Agents against Prostate Cancer

McCormick, D.L.; Rao, K.V.N.: Chemoprevention of Hormone-Dependent Prostate Cancer in the Wistar-Unilever Rat

Surrogate Endpoint Biomarkers for Clinical Trials of Prostate Cancer Chemoprevention

Montironi, R. et al.: Subtle Morphological and Molecular Changes in Normal-Looking Epithelium in Prostates with Prostatic Intraepithelial Neoplasia or Cancer

Sakr, W.A.: Prostatic Intraepithelial Neoplasia: A Marker for High-Risk Groups and a Potential Target for Chemoprevention

Qian, J.; Jenkins, R.B.; Bostwick, D.G.: Genetic and Chromosomal Alterations in Prostatic Intraepithelial Neoplasia and Carcinoma Detected by Fluorescence in situ Hybridization

Bartels, P.H. et al.: Tissue Architecture Analysis in Prostate Cancer and Its Precursors: An Innovative Approach to Computerized Histometry

Bostwick, D.G.; Neumann, R.; Qian, J.; Cheng, L.: Reversibility of Prostatic Intraepithelial Neoplasia: Implications for Chemoprevention

Algaba, F.: Evolution of Isolated High-Grade Prostatic Intraepithelial Neoplasia in a Mediterranean Patient Population

Zlotta, A.R.; Schulman, C.C.: Clinical Evolution of Prostatic Intraepithelial Neoplasia

Newling, D.: PIN I-III: When Should We Interfere?

van der Kwast, Th.H.; Labrie, F.; Têtu, B.: Prostatic Intraepithelial Neoplasia and Endocrine Manipulation

Crawford, E.D.: The Utility of Prostate-Specific Antigen as a Surrogate Marker for Identification of High-Risk Cohorts and Assessing Response in Chemoprevention Trials

Clinical Trial Designs for Chemoprevention of Prostate Cancer

van der Meijden, A.P.M.: Practical Aspects of Clinical Trials on Chemoprevention of Prostate Cancer

Sylvester, R.; Collette, L.: Statistical Considerations of Chemoprevention Clinical Trials in Prostate Cancer

Horninger, W. et al.: Prostate Cancer Screening in Tyrol, Austria: Experience and Results

Schröder, F.H. et al. (members of the ERSPC): The European Randomized Study of Screening for Prostate Cancer (ERSPC): An Update

Coltman, C.A., Jr.; Thompson, I.M., Jr.; Feigl, P.: Prostate Cancer Prevention Trial (PCPT) Update

KARGER

Order Form

Please send:

___ copy/ies: **Strategies for the Chemoprevention of Prostate Cancer**
CHF 89.- / DEM107.- / USD 77.50
ISBN 3-8055-6866-5

☐ a free sample copy of **European Urology**

☐ information on Karger publications in related fields

Postage and handling free with prepayment

For information about back volumes please contact us.

Payment

☐ Check enclosed ☐ Please bill me

Please charge this order to my credit card

☐ American Express ☐ Diners
☐ Eurocard ☐ MasterCard
☐ Visa

Card No.:

Exp. date:

Name/Address:

Date:

Signature:

Orders can be placed at agencies, bookstores, directly with the publisher, or with any Karger distributor.

S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)

Fax +41 61 306 12 34, E-Mail karger@karger.ch

USA: S. Karger Publishers, Inc., 26 West Avon Road,
P.O. Box 529, Farmington, CT 06085,
Toll free: 1-800-828-5479

Germany: S. Karger GmbH, Lörracher Str. 16A,
D-79115 Freiburg

S. Karger GmbH, Querstrasse 18, D-04103 Leipzig

France: Librairie Lugibühl, 36, bd de Latour-Maubourg,
F-75007 Paris

United Kingdom, Ireland: S. Karger AG,
58 Grove Hill Road, Tunbridge Wells, Kent TN1 1SP (UK)

Baltic States: Klanberg Ltd., Jäaraku 67, EE-12015 Tallinn
(Estonia)

India, Bangladesh, Sri Lanka:

Panther Publishers Private Ltd., 39, 6th Cross,

Wilson Gardens, Bangalore 560 027 (India)

ASEAN countries, Hong Kong, Taiwan, South Korea:

APAC, Publishers Services, Block 12,

#04-09, Lorong Bakar Batu, Kolam Ayer Industrial Estate,

Singapore 348745

Japan: Katakura Libri, Inc., 2F, Marushima Bldg,

4-6-17 Yushima, Bunkyo-ku, Tokyo 113-0034

Australia: DA Information Services, 648 Whitehorse Road,
P.O. Box 163, Mitcham, Vic. 3132

To be ordered through: